This decision expands access to renal denervation to many more patients throughout the United States. Recor Medical and Medtronic both gained FDA approval for their RDN systems in 2023, and other vendors are actively developing their own treatment options.
After President Donald Trump told reporters he underwent an MRI—adding that the results were “perfect”—it remains unclear why, exactly, the scan was ordered in the first place.
PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.
The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco.
The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.
The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.
These findings come from a new report on recruiting incentives among U.S. physicians and advanced practitioners. Interventional cardiologists earn the second highest starting salary of any specialty, with non-invasive cardiologists not far behind.
Researchers recently used advanced 4D flow MRI to track blood in a pulsating artificial heart, revealing dynamics that closely mirror those of a healthy human organ.
Congress needs to act soon to extend telemedicine services that were greatly expanded under COVID provisions, or they will expire by October. Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains concerns raised by doctors and lawmakers.
Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains the political and patient care issues involved with ending Affordable Care Act subsidies.
